Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa

European Journal of Dermatology

Volumn 22, Issue 5, 2012, Pages 640-644

  Lesage, Candice ^a   Adnot Desanlis, Lucie ^a   Perceau, Géraldine ^a   Bonnet, Morgane ^a   Palot, Jean Pierre ^b   Bernard, Philippe ^a   Reguiäi, Ziad ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b SERVICE DE DERMATOLOGIE   (France)

Author keywords

Anti TNFa; Biologics; Hidradenitis suppurativa; Infliximab

Indexed keywords

ADALIMUMAB; AMOXICILLIN; CLINDAMYCIN; DOXYCYCLINE; ETRETIN; GLUCONATE ZINC; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; PRISTINAMYCIN; RIFAMPICIN;

ABSCESS; ABSCESS AT THE SITE OF INSECT BITE; ADULT; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATOLOGY LIFE QUALITY INDEX; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR INFECTION; FEMALE; HUMAN; INTERVENTION STUDY; KERATOACANTHOMA; LONG TERM CARE; MAINTENANCE THERAPY; MALE; NOSE INFECTION; OPEN STUDY; PHARYNGITIS; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; SUPPURATIVE HIDRADENITIS; TOXIC HEPATITIS; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 84868287198     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1795     Document Type: Article

References (34)

1. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-61.
2. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-4.
3. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two casecontrol studies. J Am Acad Dermatol 2008; 59: 596-601.
4. Canoui-Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61: 51-7.
5. Konig A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatol (Basel, Switzerland). 1999; 198; 261-4.
6. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144: 809-13.
7. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-3.
8. Jemec GBE. Clinical practice. Hidradenitis suppurativa. N England J Med 2012; 366: 158-64.
9. Bordier-Lamy F, Palot JP, Vitry F, Bernard P, Grange F. Surgical treatment of hidradenitis suppurativa: a retrospective study of 93 cases. Ann Dermatol Venereol 2008; 135: 373-9.
10. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, doubleblind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
11. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Biodrug Clin Immunother Biopharm Gene Ther 2002; 16: 111-48.
12. Ostlere LS, Langtry JA, Mortimer PS, Staughton RC. Hidradenitis suppurativa in Crohn's disease. Br J Dermatol 1991; 125: 384-6.
13. Tsianos EV, Dalekos GN, Tzermias C, Merkouropoulos M, Hatzis J. Hidradenitis suppurativa in Crohn's disease. A further support to this association. J Clin Gastroenterol 1995; 20: 151-3.
14. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7: 323-6.
15. Roussomoustakaki M, Dimoulios P, Chatzicostas C, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 2003; 38: 1000-4.
16. Church JM, Fazio VW, Lavery IC, Oakley JR, Milsom JW. The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn's disease. Int J Colorectal Dis 1993; 8: 117-9.
17. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-17.
18. van der Zee HH, Laman JD, de Ruiter L, Dik WA, Prens EP. Adalimumab (antitumour necrosis factor-a) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol 2011; 166: 298-305.
19. Roy MK, Appleton MA, Delicata RJ, Sharma AK, Williams GT, Carey PD. Probable association between hidradenitis suppurativa and Crohn's disease: significance of epithelioid granuloma. Br J Surg 1997; 84: 375-6.
20. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010; 146: 501-4.
21. Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009; 60: 565-73.
22. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003; 139: 1540-2.
23. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 2002; 97: 2155-6.
24. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003; 49: 275-6.
25. Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006; 155: 1105-7.
26. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56: 624-8.
27. Fernandez-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatol (Basel, Switzerland). 2007; 215; 41-4.
28. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-4.
29. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003; 149: 1046-9.
30. Brunasso AMG, Delfino C, Massone C. Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative? Br J Dermatol 2008; 159: 761-3.
31. Barde C, Thielen AM, Kuenzli S, Saurat JH. Treatment of plaque psoriasis by sequential therapy with two 'biologics': the 'hit and run' approach, a report of two cases. Br J Dermatol 2006; 155: 211-3.
32. Brunasso AMG, Massone C. Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa. Eur J Dermatol 2010; 20: 644-6.
33. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour D, Jemec G. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 2011; 165(2): 391-8.
34. Brunasso AMG, Massone C. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab. Acta Derm Venereol 2011; 91: 70-1.